Delcath Systems/$DCTH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Delcath Systems
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
Ticker
$DCTH
Sector
Trading on
Industry
Health Care Equipment & Supplies
Headquarters
Employees
96
ISIN
US24661P8077
Website
Delcath Systems Metrics
BasicAdvanced
$537M
-
-$0.46
0.93
-
Price and volume
Market cap
$537M
Beta
0.93
52-week high
$18.23
52-week low
$7.17
Average daily volume
555K
Financial strength
Current ratio
15.954
Quick ratio
13.777
Long term debt to equity
1.129
Total debt to equity
1.266
Profitability
EBITDA (TTM)
-1.342
Gross margin (TTM)
84.90%
Net profit margin (TTM)
-26.38%
Operating margin (TTM)
-2.77%
Effective tax rate (TTM)
-1.39%
Revenue per employee (TTM)
$560,000
Management effectiveness
Return on assets (TTM)
-1.51%
Return on equity (TTM)
-28.13%
Valuation
Price to revenue (TTM)
8.868
Price to book
6.43
Price to tangible book (TTM)
6.43
Price to free cash flow (TTM)
-63.003
Free cash flow yield (TTM)
-1.59%
Free cash flow per share (TTM)
-24.49%
Growth
Revenue change (TTM)
1,068.87%
Earnings per share change (TTM)
-82.01%
3-year revenue growth (CAGR)
147.66%
10-year revenue growth (CAGR)
46.25%
3-year earnings per share growth (CAGR)
-50.06%
What the Analysts think about Delcath Systems
Analyst ratings (Buy, Hold, Sell) for Delcath Systems stock.
Bulls say / Bears say
Delcath Systems reported a significant revenue increase in Q4 2024, achieving $15.1 million compared to $0.54 million in Q4 2023, indicating strong sales growth. (Delcath Systems Reports Fourth Quarter and Full Year 2024 Results)
The company received FDA clearance for a Phase 2 trial of HEPZATO in liver-dominant metastatic colorectal cancer, potentially expanding its market reach. (Delcath Systems Reports Fourth Quarter and Full Year 2024 Results)
Delcath ended 2024 with a strong cash position of $53.2 million and operates debt-free, providing financial stability for future operations. (Delcath Systems Reports Fourth Quarter and Full Year 2024 Results)
In Q1 2025, Delcath reported earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.10, indicating potential profitability challenges. (Delcath Systems, Inc. (DCTH) Misses Q1 Earnings Estimates)
The company reported a net loss of $3.4 million in Q4 2024, despite revenue growth, highlighting ongoing profitability issues. (Delcath Systems Reports Fourth Quarter and Full Year 2024 Results)
Delcath's stock price has experienced volatility, with a 1-year range between $4.90 and $16.97, which may concern risk-averse investors. (Delcath Systems Inc (DCTH) Stock Price & News - Google Finance)
Data summarised monthly by Lightyear AI. Last updated on 6 Jun 2025.
Delcath Systems Financial Performance
Revenues and expenses
Delcath Systems Earnings Performance
Company profitability
Delcath Systems News
AllArticlesVideos
Delcath Systems to Participate at the Craig-Hallum 22nd Annual Investor Conference
Business Wire·1 month ago
Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·1 month ago
Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Delcath Systems stock?
Delcath Systems (DCTH) has a market cap of $537M as of June 18, 2025.
What is the P/E ratio for Delcath Systems stock?
The price to earnings (P/E) ratio for Delcath Systems (DCTH) stock is 0 as of June 18, 2025.
Does Delcath Systems stock pay dividends?
No, Delcath Systems (DCTH) stock does not pay dividends to its shareholders as of June 18, 2025.
When is the next Delcath Systems dividend payment date?
Delcath Systems (DCTH) stock does not pay dividends to its shareholders.
What is the beta indicator for Delcath Systems?
Delcath Systems (DCTH) has a beta rating of 0.93. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.